SERA Earnings

SERA reported its earnings on 2026-03-23, showcasing a revenue of against an estimate of 40.00K, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.17 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SERA's earnings announcement on 2026-03-23, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, SERA's stock price tends to shift by an average of 7.63% in the 10 days leading up to earnings and -6.15% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SERA's annual revenue to reach 40.00K, while the EPS is projected at -0.20. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SERA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SERA's stock price typically moves by 7.63% in the 10 days before its earnings and -6.15% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.20 and revenue of 40.00K.

The earnings call presents a mixed picture. Financial performance is weak, with a significant revenue decline, though cash reserves remain strong. The company is making strategic moves, like Medicaid pilots and European expansion, but faces regulatory and payer engagement risks. The Q&A reveals confidence in Medicaid progress and the upcoming PRIME publication, but management's reluctance to disclose economic specifics and guideline timelines adds uncertainty. Overall, the sentiment is neutral, as positive strategic developments are offset by financial challenges and uncertainties.